EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

被引：0

作者：

Yalei Yin

Mingju Sun

Xi Zhan

Changqing Wu

Pengyu Geng

Xiaoyan Sun

Yunsong Wu

Shuijun Zhang

Jianhua Qin

Zhengping Zhuang

Yang Liu

机构：

[1] Chinese Academy of Sciences,CAS Key Laboratory of Separation Science for Analytical Chemistry, Scientific Research Center for Translational Medicine, Dalian Institute of Chemical Physics

[2] Dalian University,School of Life Science

[3] National Institute of Neurological Disorders and Stroke,Surgical Neurology Branch

[4] National Institutes of Health,College of Chemistry and Molecular Sciences

[5] Wuhan University,Department of Hepatobiliary and Pancreatic Surgery

[6] The First Affiliated Hospital of Zhengzhou University,Open and Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities

[7] The First Affiliated Hospital of Zhengzhou University,undefined

[8] Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases and Organ Transplantation,undefined

[9] Henan Key Laboratory of Digestive Organ Transplantation,undefined

[10] University of Chinese Academy of Sciences,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 38卷

关键词：

Bromodomain; JQ1; MAPK pathway; MYC; EGFR mutation; Sorafenib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
Yin, Yalei
Sun, Mingju
Zhan, Xi
Wu, Changqing
Geng, Pengyu
Sun, Xiaoyan
Wu, Yunsong
Zhang, Shuijun
Qin, Jianhua
Zhuang, Zhengping
Liu, Yang
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[2] Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma
Dang, Hien
Takai, Atsushi
Forgues, Marshonna
Pomyen, Yotsowat
Mou, Haiwei
Xue, Wen
Ray, Debashish
Ha, Kevin C. H.
Morris, Quaid D.
Hughes, Timothy R.
Wang, Xin Wei
CANCER CELL, 2017, 32 (01) : 101 - +
[3] ACTIVATION OF FGF SIGNALING PATHWAY CONFERS RESISTANCE TO EGFR INHIBITION IN GBM
Guo, Gao
Gong, Ke
Sarkaria, Jann
Habib, Amyn
NEURO-ONCOLOGY, 2018, 20 : 79 - 79
[4] CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma
Jang, Jae-Woo
Song, Yeonhwa
Kim, Se-Hyuk
Kim, Jin-sun
Kim, Kang mo
Choi, Eun Kyung
Kim, Joon
Seo, Haeng Ran
CANCER LETTERS, 2017, 389 : 1 - 10
[5] Oncogenic activation of RNA binding proteins and c-Myc signaling in hepatocellular carcinoma
Hien, Dang T.
Takai, Atsushi
Forgues, Marshonna
Wang, Xin Wei
CANCER RESEARCH, 2016, 76
[6] EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
Xiaoping He
Yohko Hikiba
Yoshimasa Suzuki
Yoshinori Nakamori
Yushi Kanemaru
Makoto Sugimori
Takeshi Sato
Akito Nozaki
Makoto Chuma
Shin Maeda
Scientific Reports, 12
[7] EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
He, Xiaoping
Hikiba, Yohko
Suzuki, Yoshimasa
Nakamori, Yoshinori
Kanemaru, Yushi
Sugimori, Makoto
Sato, Takeshi
Nozaki, Akito
Chuma, Makoto
Maeda, Shin
SCIENTIFIC REPORTS, 2022, 12 (01)
[8] EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Ma, Xuhui
Wu, Shanshan
Li, Botai
Zhang, Qianqian
Zhang, Jianming
Liu, Wenming
Yan, Hexin
Bernards, Rene
Qin, Wenxin
Wang, Cun
CELL DISCOVERY, 2022, 8 (01)
[9] EGFR inhibition may overcome the resistance to lenvatinib in hepatocellular carcinoma cells
He, Xiaoping
Maeda, Shin
CANCER SCIENCE, 2022, 113 : 427 - 427
[10] EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Xuhui Ma
Shanshan Wu
Botai Li
Qianqian Zhang
Jianming Zhang
Wenming Liu
Hexin Yan
René Bernards
Wenxin Qin
Cun Wang
Cell Discovery, 8

← 1 2 3 4 5 →